Aller au contenu principal
Retour à l'annuaire
Rhumatologue

Docteur Gaëlle CLAVEL

📍 Paris 19e Arrondissement (75)HospitalierRPPS 10001850220
📊 Reconnaissance scientifique : 22/100📝 87 articles publiés📚 HAL (8)

Diplômes

🎓 DES & spécialité ordinale

  • DES Rhumatologie
  • Rhumatologie (SM)

🎓 Diplômes

  • DE Docteur en médecine

Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.

Activité de recherche & publications

Source : bases de données publiques (OpenAlex, PubMed).

h-index

22

h articles cités ≥ h fois chacun. Un h de 22 = 22 publications avec 22+ citations.

Citations

1 549

Publications

87

i10-index

33

Thématiques principales

  • Rheumatoid Arthritis Research and Therapies ×20
  • Vasculitis and related conditions ×15
  • Systemic Lupus Erythematosus Research ×11
  • Ocular Diseases and Behçet’s Syndrome ×10
  • Spondyloarthritis Studies and Treatments ×9

Affiliations FR : Université Paris Cité · Sorbonne Université · Sorbonne Paris Cité

Voir sur OpenAlex ↗🆔 ORCID 0000-0002-5905-9969

Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.

Bibliographie

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Localisation

Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.

Lieu de consultation

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

🗓 Trouver sur Doctolib📇 Ajouter à mes contacts

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

  • 1
    Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network

    Arthritis & rheumatology (Hoboken, N.J.) · 2016

    📚 116 citations🎯 RCR 6.46Top 5% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗
    Lire l'abstract Crossref ↓

    Objective To analyze the factors associated with response to anti–tumor necrosis factor (anti‐TNF) treatment and compare the efficacy and safety of infliximab (IFX) and adalimumab (ADA) in patients with refractory noninfectious uveitis. Methods This was a multicenter observational study of 160 patients (39% men and 61% women; median age 31 years [interquartile range 21–42]) with uveitis that had been refractory to other therapies, who were treated with anti‐TNF (IFX 5 mg/kg at weeks 0, 2, 6, and then every 5–6 weeks [n = 98] or ADA 40 mg every 2 weeks [n = 62]). Factors associated with complete response were assessed by multivariate analysis. Efficacy and safety of IFX versus ADA were compared using a propensity score approach with baseline characteristics taken into account. Subdistribution hazard ratios (SHRs) and 95% confidence intervals (95% CIs) were calculated. Results The main etiologies of uveitis included Behçet's disease (BD) (36%), juvenile idiopathic arthritis (22%), spondyloarthropathy (10%), and sarcoidosis (6%). The overall response rate at 6 and 12 months was 87% (26% with complete response) and 93% (28% with complete response), respectively. The median time to complete response was 2 months. In multivariate analysis, BD and occurrence of >5 uveitis flares before anti‐TNF initiation were associated with complete response to anti‐TNF (SHR 2.52 [95% CI 1.35–4.71], P = 0.004 and SHR 1.97 [95% CI 1.02–3.84], P = 0.045, respectively). Side effects were reported in 28% of patients, including serious adverse events in 13%. IFX and ADA did not differ significantly in terms of occurrence of complete response (SHR 0.65 [95% CI 0.25–1.71], P = 0.39), serious side effects (SHR 0.22 [95% CI 0.04–1.25], P = 0.089), or event‐free survival (SHR 0.55 [95% CI 0.28–1.08], P = 0.083). Conclusion Anti‐TNF treatment is highly effective in refractory inflammatory uveitis. BD is associated with increased odds of response. IFX and ADA appear to be equivalent in terms of efficacy.

  • 2
    Recent data on the role for angiogenesis in rheumatoid arthritis

    Joint bone spine · 2003

    📚 70 citations🎯 RCR 1.62
  • 3
    Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction

    Clinical immunology (Orlando, Fla.) · 2007

    📚 66 citations🎯 RCR 1.85

Publications scientifiques (41) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Transversal33

▼

Anti-TNF3

▼

Biothérapies non-anti-TNF3

▼

Essai clinique1

▼

Infiltrations1

▼

IRM ostéo-articulaire1

▼

Revue générale1

▼

Partager cette fiche

in LinkedIn🟢 WhatsApp✉ Email

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.